Adjusted ICERs for emicizumab prophylaxis among patients with haemophilia A and inhibitors compared with those without prophylaxis in India using the moderate adjustment method
| Parameters | Values |
| Monthly cost ($) of emicizumab (EMI) intervention (Ci) | 1918 |
| Mean duration of treatment (in months) for different patient age groups (Mi) | |
| 2–5 years | 48 |
| 6–10 years | 60 |
| >10 years | 312 |
| Total | 420 |
| Total cost ($) of treatment using EMI (Ci*Mi) | |
| 2–5 years | 92 063 |
| 6–10 years | 239 746 |
| >10 years | 2 194 156 |
| Total | 2 525 965 |
| Monthly cost ($) of comparator (Cc) using FEIBA | 186 748 |
| Mean duration (in months) for different patient age groups on FEIBA regimen (Mc) | |
| 2–5 years | 48 |
| 6–10 years | 60 |
| >10 years | 192 |
| Total | 300 |
| Total cost ($) of treatment using FEIBA (Cc*Mc) | |
| 2–5 years | 8 963 891 |
| 6–10 years | 23 343 465 |
| >10 years | 131 470 395 |
| Total | 163 777 751 |
| (Mi−Mc)/12 (in years) | 10 |
| Adjusted ICER ($) for India (ICERi) | Cost saving |
| Adjusted ICER (₹) for India (ICERi)* | Cost saving |
*The exchange rate used was ₹82.25 for US$1, as of 15 May 2023.
FEIBA, factor eight inhibitor bypass activity; ICER, incremental cost-effectiveness ratio.